Contineum Therapeutics files for IPO with MS drug in PhII

Kyle LaHucik

Senior Reporter

Clinical-stage biotech Contineum Therapeutics, which until recently went by the name Pipeline Therapeutics, on Friday revealed plans to go public under the Nasdaq ticker $CTNM.

The biotech’s drug PIPE-307 is being studied in patients with relapsing-remitting multiple sclerosis, or RRMS. It’s in Phase II, fitting the profile of IPO that investors have been seeking after two dismal years of new entrants to the market.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Contineum Therapeutics files for IPO with MS drug in PhII

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs

Con­tineum Ther­a­peu­tics files for IPO with MS drug in PhII

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

more like this

The next gen­er­a­tion of AI biotechs is here. Can they de­liv­er on the hype?

Bris­tol My­ers to shut­ter Bay Area cell ther­a­py R&D fa­cil­i­ty as it elim­i­nates jobs and costs

Ab­b­Vie beats first-quar­ter ex­pec­ta­tions, but Hu­mi­ra guid­ance leaves an­a­lysts con­fused

Sanders press­es phar­ma lead­ers to change stance on Pan­dem­ic Ac­cord pro­pos­als

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Contineum Therapeutics files for IPO with MS drug in PhII

The next generation of AI biotechs is here. Can they deliver on the hype?

Bristol Myers to shutter Bay Area cell therapy R&D facility as it eliminates jobs and costs

AbbVie beats first-quarter expectations, but Humira guidance leaves analysts confused

Sanders presses pharma leaders to change stance on Pandemic Accord proposals

Updated: FDA approves Pfizer’s hemophilia B gene therapy, with $3.5M price tag

UCB makes major management changes; Bristol Myers’ ADC partner tops list of new CEOs